Jeanelle Sheeder
Concepts (636)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Contraception | 19 | 2024 | 170 | 6.390 |
Why?
| | Contraceptive Agents, Female | 26 | 2024 | 80 | 4.110 |
Why?
| | Family Planning Services | 12 | 2023 | 93 | 3.170 |
Why?
| | Contraception Behavior | 19 | 2024 | 108 | 3.070 |
Why?
| | Desogestrel | 22 | 2024 | 46 | 3.000 |
Why?
| | Contraceptive Agents | 7 | 2023 | 66 | 3.000 |
Why?
| | Pregnancy in Adolescence | 18 | 2024 | 83 | 2.880 |
Why?
| | Abortion, Induced | 15 | 2025 | 113 | 2.830 |
Why?
| | Pregnancy | 82 | 2025 | 7276 | 2.230 |
Why?
| | Long-Acting Reversible Contraception | 9 | 2024 | 34 | 2.220 |
Why?
| | Drug Implants | 20 | 2024 | 83 | 1.840 |
Why?
| | Prenatal Care | 9 | 2020 | 310 | 1.780 |
Why?
| | Hospitals, Religious | 5 | 2020 | 5 | 1.560 |
Why?
| | Gynecology | 11 | 2026 | 184 | 1.540 |
Why?
| | Adolescent Health Services | 4 | 2024 | 74 | 1.490 |
Why?
| | Counseling | 6 | 2020 | 407 | 1.410 |
Why?
| | Intrauterine Devices | 7 | 2019 | 29 | 1.410 |
Why?
| | Female | 176 | 2026 | 80081 | 1.400 |
Why?
| | Health Knowledge, Attitudes, Practice | 12 | 2025 | 1431 | 1.400 |
Why?
| | Postpartum Period | 11 | 2024 | 379 | 1.400 |
Why?
| | Adolescent | 92 | 2026 | 22826 | 1.390 |
Why?
| | Young Adult | 68 | 2025 | 14437 | 1.300 |
Why?
| | Obstetrics | 9 | 2026 | 179 | 1.300 |
Why?
| | Adolescent Behavior | 9 | 2015 | 498 | 1.280 |
Why?
| | Pregnancy Outcome | 10 | 2025 | 506 | 1.100 |
Why?
| | Humans | 193 | 2026 | 147306 | 1.070 |
Why?
| | Colorado | 36 | 2025 | 4591 | 1.060 |
Why?
| | Reproductive Health | 4 | 2023 | 94 | 1.050 |
Why?
| | Catholicism | 5 | 2020 | 9 | 1.030 |
Why?
| | Contraception, Postcoital | 2 | 2025 | 9 | 1.030 |
Why?
| | Endometrial Neoplasms | 10 | 2022 | 205 | 1.030 |
Why?
| | Chlamydia Infections | 3 | 2024 | 79 | 1.020 |
Why?
| | Health Personnel | 2 | 2025 | 762 | 0.970 |
Why?
| | Contraceptives, Oral, Combined | 2 | 2023 | 18 | 0.890 |
Why?
| | Adult | 95 | 2026 | 41406 | 0.870 |
Why?
| | Cross-Sectional Studies | 27 | 2026 | 6011 | 0.840 |
Why?
| | Postnatal Care | 3 | 2021 | 76 | 0.840 |
Why?
| | Trichomonas Infections | 1 | 2024 | 11 | 0.810 |
Why?
| | Trichomonas vaginalis | 1 | 2024 | 11 | 0.810 |
Why?
| | Substance Abuse Detection | 1 | 2025 | 112 | 0.800 |
Why?
| | Surveys and Questionnaires | 28 | 2026 | 6164 | 0.800 |
Why?
| | Patient Acceptance of Health Care | 3 | 2020 | 895 | 0.800 |
Why?
| | Confidentiality | 1 | 2024 | 80 | 0.790 |
Why?
| | Patient Satisfaction | 6 | 2025 | 718 | 0.780 |
Why?
| | Healthcare Disparities | 3 | 2025 | 741 | 0.780 |
Why?
| | Sexual Behavior | 7 | 2022 | 502 | 0.770 |
Why?
| | Enoxaparin | 2 | 2020 | 68 | 0.750 |
Why?
| | Religion and Medicine | 3 | 2020 | 33 | 0.710 |
Why?
| | Pyridones | 2 | 2020 | 210 | 0.690 |
Why?
| | Sexually Transmitted Diseases | 1 | 2024 | 168 | 0.690 |
Why?
| | Levonorgestrel | 4 | 2018 | 34 | 0.640 |
Why?
| | Parity | 5 | 2016 | 112 | 0.620 |
Why?
| | Ambulatory Care Facilities | 5 | 2024 | 269 | 0.620 |
Why?
| | Group Processes | 2 | 2018 | 63 | 0.610 |
Why?
| | Mothers | 5 | 2022 | 774 | 0.610 |
Why?
| | Religion and Psychology | 1 | 2019 | 27 | 0.600 |
Why?
| | Hysterectomy | 6 | 2019 | 138 | 0.590 |
Why?
| | Pyrazoles | 2 | 2020 | 518 | 0.590 |
Why?
| | Health Services Accessibility | 5 | 2026 | 1122 | 0.590 |
Why?
| | Postoperative Hemorrhage | 1 | 2020 | 106 | 0.580 |
Why?
| | Venous Thromboembolism | 2 | 2020 | 330 | 0.580 |
Why?
| | Patient-Centered Care | 2 | 2021 | 552 | 0.570 |
Why?
| | Intention | 5 | 2024 | 187 | 0.570 |
Why?
| | Sex Offenses | 1 | 2022 | 199 | 0.570 |
Why?
| | Pregnancy Rate | 2 | 2017 | 83 | 0.570 |
Why?
| | Community Health Services | 2 | 2023 | 231 | 0.570 |
Why?
| | Financial Support | 1 | 2018 | 18 | 0.550 |
Why?
| | Vulnerable Populations | 1 | 2020 | 177 | 0.550 |
Why?
| | Health Care Sector | 1 | 2018 | 26 | 0.550 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1379 | 0.550 |
Why?
| | Intrauterine Devices, Copper | 5 | 2018 | 7 | 0.550 |
Why?
| | Rural Health Services | 1 | 2019 | 139 | 0.540 |
Why?
| | Ovarian Neoplasms | 6 | 2020 | 599 | 0.540 |
Why?
| | Pregnancy, Unplanned | 3 | 2017 | 48 | 0.540 |
Why?
| | Prosthesis Implantation | 2 | 2017 | 156 | 0.520 |
Why?
| | Fibrinolytic Agents | 1 | 2020 | 303 | 0.520 |
Why?
| | Premature Birth | 2 | 2025 | 390 | 0.490 |
Why?
| | Luteal Phase | 1 | 2017 | 51 | 0.490 |
Why?
| | Retrospective Studies | 36 | 2025 | 17561 | 0.490 |
Why?
| | Intrauterine Devices, Medicated | 6 | 2017 | 27 | 0.490 |
Why?
| | Chlamydia trachomatis | 3 | 2024 | 49 | 0.480 |
Why?
| | Delivery of Health Care | 2 | 2023 | 951 | 0.480 |
Why?
| | Infant, Low Birth Weight | 2 | 2015 | 156 | 0.480 |
Why?
| | Lacerations | 3 | 2022 | 40 | 0.460 |
Why?
| | Parenting | 1 | 2020 | 320 | 0.460 |
Why?
| | Depression, Postpartum | 3 | 2020 | 117 | 0.460 |
Why?
| | Interprofessional Relations | 1 | 2018 | 276 | 0.460 |
Why?
| | Substance-Related Disorders | 1 | 2025 | 1112 | 0.460 |
Why?
| | Group Structure | 1 | 2015 | 2 | 0.450 |
Why?
| | Life Style | 4 | 2024 | 504 | 0.440 |
Why?
| | Risk | 2 | 2017 | 927 | 0.440 |
Why?
| | Guatemala | 3 | 2021 | 347 | 0.440 |
Why?
| | Perimenopause | 1 | 2015 | 69 | 0.430 |
Why?
| | Carcinoma, Endometrioid | 3 | 2022 | 49 | 0.430 |
Why?
| | Genital Neoplasms, Female | 4 | 2020 | 100 | 0.430 |
Why?
| | Fertility Preservation | 3 | 2023 | 57 | 0.420 |
Why?
| | Uterus | 1 | 2015 | 228 | 0.410 |
Why?
| | Safety-net Providers | 1 | 2015 | 132 | 0.400 |
Why?
| | Multicenter Studies as Topic | 1 | 2015 | 417 | 0.400 |
Why?
| | Patient Selection | 3 | 2015 | 746 | 0.400 |
Why?
| | Maternal Age | 3 | 2018 | 129 | 0.390 |
Why?
| | Middle Aged | 41 | 2026 | 36821 | 0.390 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2019 | 1777 | 0.390 |
Why?
| | Attitude to Health | 3 | 2020 | 431 | 0.380 |
Why?
| | Goals | 1 | 2014 | 186 | 0.370 |
Why?
| | Quality Improvement | 5 | 2025 | 1321 | 0.370 |
Why?
| | Primary Health Care | 4 | 2023 | 1760 | 0.360 |
Why?
| | Choice Behavior | 3 | 2019 | 181 | 0.360 |
Why?
| | Estradiol | 1 | 2015 | 515 | 0.350 |
Why?
| | Uterine Cervical Neoplasms | 3 | 2021 | 268 | 0.350 |
Why?
| | Mass Screening | 9 | 2023 | 1375 | 0.340 |
Why?
| | Papillomavirus Vaccines | 1 | 2015 | 296 | 0.340 |
Why?
| | Child | 20 | 2026 | 22980 | 0.340 |
Why?
| | Internship and Residency | 6 | 2023 | 1279 | 0.340 |
Why?
| | Progesterone | 2 | 2025 | 215 | 0.340 |
Why?
| | Gestational Age | 5 | 2024 | 997 | 0.330 |
Why?
| | Delivery, Obstetric | 5 | 2025 | 164 | 0.330 |
Why?
| | Obstetric Labor Complications | 2 | 2022 | 38 | 0.330 |
Why?
| | Depression | 5 | 2026 | 1599 | 0.320 |
Why?
| | Disclosure | 2 | 2022 | 87 | 0.310 |
Why?
| | Magnetoencephalography | 13 | 2000 | 161 | 0.310 |
Why?
| | Postoperative Complications | 9 | 2020 | 3022 | 0.310 |
Why?
| | Male | 48 | 2026 | 73954 | 0.310 |
Why?
| | United States | 20 | 2025 | 16313 | 0.300 |
Why?
| | Functional Laterality | 11 | 2001 | 241 | 0.300 |
Why?
| | Health Behavior | 1 | 2015 | 799 | 0.300 |
Why?
| | Socioeconomic Factors | 5 | 2021 | 1342 | 0.290 |
Why?
| | Lymph Nodes | 3 | 2018 | 514 | 0.290 |
Why?
| | Nurse Midwives | 2 | 2020 | 43 | 0.290 |
Why?
| | Condoms | 3 | 2017 | 102 | 0.290 |
Why?
| | Feasibility Studies | 7 | 2022 | 1147 | 0.290 |
Why?
| | Evoked Potentials, Auditory | 10 | 2001 | 181 | 0.290 |
Why?
| | Birth Intervals | 2 | 2019 | 23 | 0.290 |
Why?
| | Attitude of Health Personnel | 3 | 2024 | 1220 | 0.280 |
Why?
| | Robotic Surgical Procedures | 3 | 2016 | 207 | 0.270 |
Why?
| | Intrauterine Device Expulsion | 3 | 2017 | 9 | 0.270 |
Why?
| | Communication | 3 | 2022 | 989 | 0.270 |
Why?
| | Infant, Small for Gestational Age | 2 | 2019 | 118 | 0.260 |
Why?
| | Patient Participation | 1 | 2012 | 449 | 0.260 |
Why?
| | Women's Health | 2 | 2020 | 317 | 0.260 |
Why?
| | Time Factors | 12 | 2024 | 7173 | 0.260 |
Why?
| | Sexual Partners | 3 | 2024 | 195 | 0.260 |
Why?
| | Attitude | 3 | 2019 | 260 | 0.250 |
Why?
| | Prediabetic State | 2 | 2023 | 251 | 0.250 |
Why?
| | Uterine Cervicitis | 1 | 2006 | 7 | 0.240 |
Why?
| | Cohort Studies | 11 | 2021 | 6099 | 0.240 |
Why?
| | Vaccination | 1 | 2015 | 1443 | 0.240 |
Why?
| | Organizational Policy | 2 | 2019 | 78 | 0.240 |
Why?
| | Pregnancy Complications | 4 | 2019 | 607 | 0.240 |
Why?
| | Age Factors | 8 | 2016 | 3372 | 0.230 |
Why?
| | Perineum | 3 | 2022 | 37 | 0.230 |
Why?
| | Arthritis, Juvenile | 1 | 2026 | 64 | 0.230 |
Why?
| | Analgesia, Obstetrical | 1 | 2025 | 33 | 0.220 |
Why?
| | Marijuana Use | 2 | 2019 | 222 | 0.220 |
Why?
| | Cerclage, Cervical | 1 | 2025 | 11 | 0.220 |
Why?
| | Pregnancy Trimester, First | 4 | 2023 | 139 | 0.220 |
Why?
| | Cesarean Section | 2 | 2025 | 230 | 0.220 |
Why?
| | Prospective Studies | 14 | 2022 | 8166 | 0.220 |
Why?
| | Gelatin | 2 | 2016 | 56 | 0.220 |
Why?
| | Electronics, Medical | 1 | 2004 | 7 | 0.220 |
Why?
| | Perinatal Care | 1 | 2025 | 61 | 0.220 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2023 | 2627 | 0.220 |
Why?
| | Fetal Death | 2 | 2016 | 59 | 0.210 |
Why?
| | Laparotomy | 2 | 2015 | 113 | 0.210 |
Why?
| | Progestins | 1 | 2025 | 67 | 0.210 |
Why?
| | Labor, Induced | 1 | 2025 | 40 | 0.210 |
Why?
| | Aged, 80 and over | 11 | 2021 | 8432 | 0.210 |
Why?
| | Legal Guardians | 1 | 2024 | 10 | 0.210 |
Why?
| | Database Management Systems | 1 | 2004 | 51 | 0.210 |
Why?
| | Weight Gain | 6 | 2021 | 566 | 0.210 |
Why?
| | Thrombin | 2 | 2016 | 174 | 0.210 |
Why?
| | Midwifery | 1 | 2025 | 68 | 0.200 |
Why?
| | Contact Tracing | 1 | 2024 | 26 | 0.200 |
Why?
| | Privacy | 1 | 2024 | 41 | 0.200 |
Why?
| | Aromatherapy | 1 | 2023 | 2 | 0.200 |
Why?
| | Aged | 18 | 2021 | 26516 | 0.200 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1167 | 0.200 |
Why?
| | Scapula | 1 | 2024 | 48 | 0.200 |
Why?
| | Pregnancy Trimester, Second | 4 | 2018 | 92 | 0.200 |
Why?
| | Clinical Competence | 3 | 2018 | 1260 | 0.200 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2026 | 242 | 0.200 |
Why?
| | Contraceptive Devices | 1 | 2023 | 3 | 0.200 |
Why?
| | Ethinyl Estradiol | 1 | 2023 | 16 | 0.200 |
Why?
| | Pediatricians | 1 | 2024 | 121 | 0.200 |
Why?
| | Birth Weight | 1 | 2006 | 522 | 0.190 |
Why?
| | Cost-Benefit Analysis | 3 | 2020 | 654 | 0.190 |
Why?
| | Telemedicine | 2 | 2023 | 978 | 0.190 |
Why?
| | Social Support | 2 | 2020 | 655 | 0.190 |
Why?
| | Patient Health Questionnaire | 1 | 2023 | 44 | 0.190 |
Why?
| | Fellowships and Scholarships | 2 | 2018 | 357 | 0.190 |
Why?
| | Fertility | 3 | 2023 | 175 | 0.190 |
Why?
| | Physician's Role | 1 | 2024 | 225 | 0.190 |
Why?
| | Pain | 2 | 2018 | 794 | 0.190 |
Why?
| | Device Removal | 1 | 2024 | 149 | 0.190 |
Why?
| | Leuprolide | 1 | 2022 | 21 | 0.190 |
Why?
| | House Calls | 2 | 2019 | 154 | 0.180 |
Why?
| | Decision Making | 4 | 2016 | 994 | 0.180 |
Why?
| | Semen | 1 | 2022 | 24 | 0.180 |
Why?
| | Pediatrics | 2 | 2024 | 1139 | 0.180 |
Why?
| | Abortion, Spontaneous | 1 | 2023 | 119 | 0.180 |
Why?
| | Anxiety | 3 | 2026 | 1149 | 0.180 |
Why?
| | Pregnancy Tests | 2 | 2017 | 11 | 0.180 |
Why?
| | Patient Preference | 2 | 2015 | 225 | 0.180 |
Why?
| | Exercise | 3 | 2024 | 2219 | 0.170 |
Why?
| | Treatment Adherence and Compliance | 1 | 2021 | 27 | 0.170 |
Why?
| | Infant, Newborn | 8 | 2025 | 6543 | 0.170 |
Why?
| | Chorioamnionitis | 1 | 2021 | 50 | 0.170 |
Why?
| | Students, Medical | 2 | 2016 | 380 | 0.160 |
Why?
| | beta Catenin | 2 | 2022 | 254 | 0.160 |
Why?
| | Maternal-Child Health Services | 1 | 2020 | 12 | 0.160 |
Why?
| | Pilot Projects | 4 | 2024 | 1912 | 0.160 |
Why?
| | Lymph Node Excision | 3 | 2018 | 173 | 0.160 |
Why?
| | Decision Support Techniques | 2 | 2020 | 480 | 0.160 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 1999 | 39 | 0.160 |
Why?
| | Self Report | 3 | 2021 | 887 | 0.160 |
Why?
| | Parturition | 2 | 2019 | 73 | 0.160 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 126 | 0.160 |
Why?
| | Magnetics | 2 | 1999 | 46 | 0.150 |
Why?
| | Accelerometry | 1 | 2021 | 126 | 0.150 |
Why?
| | Home Health Nursing | 1 | 2019 | 13 | 0.150 |
Why?
| | Patient Education as Topic | 3 | 2019 | 781 | 0.150 |
Why?
| | Uterine Hemorrhage | 2 | 2021 | 41 | 0.150 |
Why?
| | Menstruation Disturbances | 1 | 2019 | 13 | 0.150 |
Why?
| | Health Facilities | 1 | 2020 | 85 | 0.150 |
Why?
| | Pharmacogenetics | 1 | 2021 | 176 | 0.150 |
Why?
| | Outpatients | 3 | 2023 | 450 | 0.150 |
Why?
| | Factor Analysis, Statistical | 1 | 2020 | 296 | 0.150 |
Why?
| | Hysterectomy, Vaginal | 1 | 2019 | 6 | 0.150 |
Why?
| | Cytochrome P450 Family 3 | 1 | 2019 | 3 | 0.150 |
Why?
| | Dietary Supplements | 1 | 2023 | 586 | 0.150 |
Why?
| | Ambulatory Surgical Procedures | 2 | 2017 | 79 | 0.150 |
Why?
| | Cues | 1 | 2022 | 329 | 0.150 |
Why?
| | Vaginosis, Bacterial | 1 | 2019 | 10 | 0.150 |
Why?
| | Candidiasis, Vulvovaginal | 1 | 2019 | 5 | 0.150 |
Why?
| | Body Mass Index | 5 | 2024 | 2470 | 0.150 |
Why?
| | Insulin Resistance | 2 | 2008 | 1253 | 0.140 |
Why?
| | Clothing | 1 | 2019 | 23 | 0.140 |
Why?
| | Hygiene | 1 | 2019 | 29 | 0.140 |
Why?
| | Neoplasm Staging | 6 | 2020 | 1492 | 0.140 |
Why?
| | Transgender Persons | 1 | 2022 | 214 | 0.140 |
Why?
| | Double-Blind Method | 5 | 2018 | 2080 | 0.140 |
Why?
| | Anesthesia, Inhalation | 1 | 2018 | 14 | 0.140 |
Why?
| | Anesthesia, Intravenous | 1 | 2018 | 24 | 0.140 |
Why?
| | Live Birth | 1 | 2019 | 81 | 0.140 |
Why?
| | Cancer Pain | 1 | 2019 | 41 | 0.140 |
Why?
| | Medical Oncology | 2 | 2019 | 344 | 0.140 |
Why?
| | Obesity | 5 | 2016 | 3149 | 0.140 |
Why?
| | Nitrous Oxide | 1 | 2018 | 34 | 0.140 |
Why?
| | Anesthetics, Intravenous | 1 | 2018 | 69 | 0.140 |
Why?
| | Models, Anatomic | 1 | 2019 | 87 | 0.140 |
Why?
| | Genitalia, Female | 1 | 2018 | 43 | 0.140 |
Why?
| | Physician Assistants | 1 | 2020 | 101 | 0.140 |
Why?
| | Databases as Topic | 2 | 2008 | 71 | 0.140 |
Why?
| | Databases, Factual | 3 | 2021 | 1504 | 0.140 |
Why?
| | Anesthetics, Inhalation | 1 | 2018 | 52 | 0.140 |
Why?
| | Hemostasis, Surgical | 2 | 2016 | 25 | 0.130 |
Why?
| | Treatment Outcome | 10 | 2020 | 11947 | 0.130 |
Why?
| | Ovariectomy | 2 | 2015 | 166 | 0.130 |
Why?
| | Off-Label Use | 1 | 2018 | 51 | 0.130 |
Why?
| | Risk-Taking | 2 | 2019 | 325 | 0.130 |
Why?
| | Culture | 1 | 2019 | 126 | 0.130 |
Why?
| | Organ Transplantation | 1 | 2021 | 258 | 0.130 |
Why?
| | Conflict of Interest | 1 | 2018 | 55 | 0.130 |
Why?
| | Nurse Practitioners | 1 | 2020 | 142 | 0.130 |
Why?
| | Logistic Models | 6 | 2024 | 2142 | 0.130 |
Why?
| | Oncologists | 1 | 2018 | 47 | 0.130 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2018 | 103 | 0.130 |
Why?
| | Psychometrics | 4 | 2009 | 739 | 0.130 |
Why?
| | Adenocarcinoma | 2 | 2015 | 928 | 0.130 |
Why?
| | Commerce | 1 | 2018 | 81 | 0.130 |
Why?
| | Sterilization, Reproductive | 1 | 2017 | 8 | 0.130 |
Why?
| | Demyelinating Diseases | 1 | 1998 | 84 | 0.130 |
Why?
| | Hysteroscopy | 1 | 2017 | 14 | 0.130 |
Why?
| | Quality of Health Care | 2 | 2021 | 697 | 0.130 |
Why?
| | Polymorphism, Genetic | 1 | 2019 | 615 | 0.120 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2018 | 77 | 0.120 |
Why?
| | Professional-Patient Relations | 1 | 2018 | 149 | 0.120 |
Why?
| | Salpingectomy | 2 | 2015 | 15 | 0.120 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2017 | 30 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 2001 | 0.120 |
Why?
| | Abortion, Therapeutic | 1 | 2016 | 3 | 0.120 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 212 | 0.120 |
Why?
| | Dilatation and Curettage | 1 | 2016 | 13 | 0.120 |
Why?
| | Brain Diseases | 1 | 1998 | 158 | 0.120 |
Why?
| | Ultrasonography | 2 | 2019 | 795 | 0.120 |
Why?
| | Incidence | 5 | 2019 | 2954 | 0.120 |
Why?
| | Pelvic Infection | 1 | 2016 | 6 | 0.120 |
Why?
| | Surgeons | 2 | 2018 | 342 | 0.120 |
Why?
| | Family | 1 | 2021 | 690 | 0.120 |
Why?
| | Medical Marijuana | 1 | 2018 | 122 | 0.120 |
Why?
| | Minority Groups | 1 | 2018 | 286 | 0.120 |
Why?
| | Tissue Adhesives | 1 | 2016 | 21 | 0.120 |
Why?
| | Bipolar Disorder | 1 | 1999 | 307 | 0.120 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2017 | 75 | 0.120 |
Why?
| | Follow-Up Studies | 8 | 2019 | 5478 | 0.120 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2015 | 33 | 0.120 |
Why?
| | Pregnancy, Unwanted | 1 | 2015 | 15 | 0.120 |
Why?
| | Quality of Life | 2 | 2026 | 3246 | 0.110 |
Why?
| | Weight Reduction Programs | 1 | 2017 | 141 | 0.110 |
Why?
| | Cerebral Cortex | 1 | 1999 | 483 | 0.110 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 334 | 0.110 |
Why?
| | Administration, Cutaneous | 1 | 2015 | 127 | 0.110 |
Why?
| | Risk Reduction Behavior | 2 | 2014 | 221 | 0.110 |
Why?
| | Internet | 2 | 2019 | 696 | 0.110 |
Why?
| | Infant | 3 | 2023 | 10195 | 0.110 |
Why?
| | Placebos | 1 | 2015 | 193 | 0.110 |
Why?
| | Patient Compliance | 2 | 2012 | 591 | 0.110 |
Why?
| | Ambulatory Care | 1 | 2020 | 625 | 0.110 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1998 | 627 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 7 | 2001 | 3980 | 0.110 |
Why?
| | Interpersonal Relations | 2 | 2017 | 403 | 0.110 |
Why?
| | Contraceptives, Oral | 1 | 2015 | 37 | 0.110 |
Why?
| | Hot Flashes | 1 | 2015 | 92 | 0.110 |
Why?
| | Papillomaviridae | 1 | 2015 | 116 | 0.110 |
Why?
| | Radiography, Thoracic | 1 | 2016 | 173 | 0.110 |
Why?
| | Anticoagulants | 1 | 2020 | 751 | 0.110 |
Why?
| | Physician-Patient Relations | 2 | 2019 | 594 | 0.110 |
Why?
| | Advanced Practice Nursing | 1 | 2015 | 45 | 0.100 |
Why?
| | Abdominal Abscess | 1 | 2014 | 28 | 0.100 |
Why?
| | Delayed-Action Preparations | 1 | 2015 | 191 | 0.100 |
Why?
| | Pandemics | 1 | 2023 | 1720 | 0.100 |
Why?
| | Curriculum | 3 | 2018 | 1083 | 0.100 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 196 | 0.100 |
Why?
| | Risk Factors | 10 | 2022 | 11017 | 0.100 |
Why?
| | Immunization Schedule | 1 | 2015 | 186 | 0.100 |
Why?
| | Schizophrenia | 4 | 2000 | 489 | 0.100 |
Why?
| | Genetic Variation | 1 | 2019 | 995 | 0.100 |
Why?
| | Neoplasm Grading | 3 | 2022 | 313 | 0.100 |
Why?
| | Endometrium | 1 | 2014 | 64 | 0.100 |
Why?
| | Glycoproteins | 1 | 2015 | 358 | 0.100 |
Why?
| | Digoxin | 1 | 2013 | 27 | 0.100 |
Why?
| | Fatigue | 1 | 2015 | 367 | 0.100 |
Why?
| | Otolaryngology | 1 | 2015 | 108 | 0.100 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2013 | 19 | 0.100 |
Why?
| | Pelvic Neoplasms | 1 | 2013 | 24 | 0.100 |
Why?
| | Robotics | 1 | 2014 | 90 | 0.090 |
Why?
| | Umbilical Cord | 1 | 2013 | 93 | 0.090 |
Why?
| | Motivational Interviewing | 1 | 2014 | 122 | 0.090 |
Why?
| | Brain | 8 | 2001 | 3009 | 0.090 |
Why?
| | Peer Group | 1 | 2015 | 258 | 0.090 |
Why?
| | Travel | 2 | 2024 | 136 | 0.090 |
Why?
| | Antigens, CD | 1 | 2015 | 562 | 0.090 |
Why?
| | Overweight | 1 | 2017 | 617 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1166 | 0.090 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2013 | 90 | 0.090 |
Why?
| | Drug Monitoring | 1 | 2015 | 402 | 0.090 |
Why?
| | Neoplastic Stem Cells | 1 | 2015 | 409 | 0.090 |
Why?
| | School Health Services | 1 | 2014 | 222 | 0.090 |
Why?
| | Guideline Adherence | 2 | 2021 | 590 | 0.080 |
Why?
| | Abortion Applicants | 1 | 2010 | 3 | 0.080 |
Why?
| | Papillomavirus Infections | 1 | 2015 | 345 | 0.080 |
Why?
| | Glucose Tolerance Test | 2 | 2013 | 361 | 0.080 |
Why?
| | Opioid-Related Disorders | 1 | 2019 | 617 | 0.080 |
Why?
| | Odds Ratio | 2 | 2016 | 1084 | 0.080 |
Why?
| | Hemorrhage | 1 | 2016 | 832 | 0.080 |
Why?
| | Domestic Violence | 1 | 2010 | 51 | 0.080 |
Why?
| | Anal Canal | 2 | 2022 | 102 | 0.080 |
Why?
| | Health Care Costs | 1 | 2014 | 428 | 0.080 |
Why?
| | Rural Population | 3 | 2022 | 685 | 0.080 |
Why?
| | Blood Loss, Surgical | 3 | 2016 | 116 | 0.080 |
Why?
| | Education, Medical, Graduate | 1 | 2015 | 568 | 0.080 |
Why?
| | Clinical Clerkship | 1 | 2011 | 109 | 0.080 |
Why?
| | Pediatric Obesity | 1 | 2017 | 640 | 0.080 |
Why?
| | Pain Measurement | 2 | 2025 | 569 | 0.080 |
Why?
| | Neoplasm Invasiveness | 3 | 2017 | 512 | 0.080 |
Why?
| | Peptides | 1 | 2015 | 1003 | 0.080 |
Why?
| | Linear Models | 3 | 2019 | 852 | 0.080 |
Why?
| | Misoprostol | 1 | 2009 | 15 | 0.070 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 2009 | 20 | 0.070 |
Why?
| | Latin America | 1 | 2009 | 96 | 0.070 |
Why?
| | Preoperative Care | 3 | 2017 | 381 | 0.070 |
Why?
| | Risk Assessment | 4 | 2016 | 3784 | 0.070 |
Why?
| | Research Design | 1 | 2015 | 1158 | 0.070 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 67 | 0.070 |
Why?
| | Personality Inventory | 1 | 2009 | 134 | 0.070 |
Why?
| | Medical Records Systems, Computerized | 1 | 2009 | 96 | 0.070 |
Why?
| | Interferon-beta | 2 | 2000 | 92 | 0.070 |
Why?
| | Dominance, Cerebral | 2 | 2000 | 58 | 0.070 |
Why?
| | Case-Control Studies | 5 | 2020 | 3660 | 0.070 |
Why?
| | Sleep | 1 | 2015 | 895 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2012 | 563 | 0.070 |
Why?
| | Menarche | 1 | 2008 | 53 | 0.070 |
Why?
| | Referral and Consultation | 2 | 2018 | 886 | 0.070 |
Why?
| | Nausea | 2 | 2019 | 112 | 0.070 |
Why?
| | Smoking | 1 | 2015 | 1483 | 0.070 |
Why?
| | Multivariate Analysis | 2 | 2025 | 1550 | 0.070 |
Why?
| | Sex Factors | 6 | 2020 | 2136 | 0.070 |
Why?
| | Temporal Lobe | 3 | 1997 | 113 | 0.070 |
Why?
| | Breast Feeding | 1 | 2012 | 447 | 0.070 |
Why?
| | Schizophrenia, Paranoid | 2 | 1997 | 9 | 0.070 |
Why?
| | Weight Loss | 2 | 2017 | 867 | 0.070 |
Why?
| | Psychotic Disorders | 2 | 2000 | 199 | 0.060 |
Why?
| | Comorbidity | 2 | 2016 | 1672 | 0.060 |
Why?
| | Reference Values | 3 | 2018 | 800 | 0.060 |
Why?
| | Societies, Medical | 3 | 2018 | 914 | 0.060 |
Why?
| | Students, Health Occupations | 1 | 2007 | 37 | 0.060 |
Why?
| | Healthy Volunteers | 2 | 2019 | 219 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 536 | 0.060 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 97 | 0.060 |
Why?
| | Fathers | 1 | 2006 | 53 | 0.060 |
Why?
| | False Positive Reactions | 1 | 2006 | 124 | 0.060 |
Why?
| | Science | 1 | 2007 | 55 | 0.060 |
Why?
| | Severity of Illness Index | 3 | 2026 | 2974 | 0.060 |
Why?
| | Auditory Cortex | 2 | 1997 | 46 | 0.060 |
Why?
| | Urethritis | 1 | 2005 | 4 | 0.060 |
Why?
| | Azithromycin | 1 | 2006 | 101 | 0.060 |
Why?
| | Uterine Cervical Diseases | 1 | 2005 | 6 | 0.060 |
Why?
| | Prognosis | 4 | 2018 | 4384 | 0.060 |
Why?
| | Maternal Health Services | 1 | 2007 | 101 | 0.060 |
Why?
| | Prevalence | 2 | 2017 | 2889 | 0.060 |
Why?
| | Self Efficacy | 2 | 2019 | 423 | 0.050 |
Why?
| | Fatty Liver | 1 | 2008 | 257 | 0.050 |
Why?
| | Dilatation | 1 | 2025 | 73 | 0.050 |
Why?
| | Length of Stay | 3 | 2015 | 1371 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 1998 | 2420 | 0.050 |
Why?
| | Chronic Disease | 2 | 2024 | 1845 | 0.050 |
Why?
| | Teaching | 1 | 2007 | 243 | 0.050 |
Why?
| | Metformin | 1 | 2008 | 329 | 0.050 |
Why?
| | Herb-Drug Interactions | 1 | 2023 | 4 | 0.050 |
Why?
| | Metabolic Syndrome | 1 | 2008 | 365 | 0.050 |
Why?
| | Acanthosis Nigricans | 1 | 2003 | 4 | 0.050 |
Why?
| | Hospitals, University | 2 | 2016 | 176 | 0.050 |
Why?
| | Texas | 1 | 2024 | 278 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 2015 | 1281 | 0.050 |
Why?
| | Diagnosis, Differential | 2 | 2008 | 1518 | 0.050 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2023 | 5 | 0.050 |
Why?
| | Biomarkers, Tumor | 2 | 2022 | 1339 | 0.050 |
Why?
| | Ovulation | 1 | 2023 | 46 | 0.050 |
Why?
| | Program Evaluation | 2 | 2019 | 952 | 0.050 |
Why?
| | Urban Population | 2 | 2016 | 502 | 0.050 |
Why?
| | Rifampin | 1 | 2023 | 79 | 0.050 |
Why?
| | Diet | 2 | 2024 | 1284 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2679 | 0.050 |
Why?
| | Episiotomy | 1 | 2022 | 5 | 0.040 |
Why?
| | Longitudinal Studies | 3 | 2017 | 3029 | 0.040 |
Why?
| | Pregnancy, Twin | 1 | 2021 | 19 | 0.040 |
Why?
| | Menstrual Cycle | 1 | 2022 | 145 | 0.040 |
Why?
| | Pain Management | 1 | 2025 | 415 | 0.040 |
Why?
| | Pharmacogenomic Variants | 1 | 2021 | 35 | 0.040 |
Why?
| | Neoplasms | 1 | 2016 | 2946 | 0.040 |
Why?
| | Reproduction | 1 | 2022 | 212 | 0.040 |
Why?
| | Alpha Rhythm | 1 | 2000 | 11 | 0.040 |
Why?
| | Anti-Bacterial Agents | 2 | 2014 | 1940 | 0.040 |
Why?
| | Analysis of Variance | 5 | 2005 | 1302 | 0.040 |
Why?
| | Time-to-Pregnancy | 1 | 2020 | 3 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 50 | 0.040 |
Why?
| | Biomedical Research | 1 | 2007 | 723 | 0.040 |
Why?
| | Wrist | 1 | 2021 | 60 | 0.040 |
Why?
| | Coitus | 2 | 2011 | 24 | 0.040 |
Why?
| | Mother-Child Relations | 1 | 2021 | 131 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2019 | 20 | 0.040 |
Why?
| | Refractory Period, Electrophysiological | 1 | 1999 | 5 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2019 | 29 | 0.040 |
Why?
| | Ethics, Medical | 1 | 2020 | 93 | 0.040 |
Why?
| | Poverty | 2 | 2017 | 533 | 0.040 |
Why?
| | Median Nerve | 1 | 1999 | 26 | 0.040 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 69 | 0.040 |
Why?
| | Ethics, Institutional | 1 | 2019 | 4 | 0.040 |
Why?
| | Visible Human Projects | 1 | 2019 | 2 | 0.040 |
Why?
| | Needs Assessment | 2 | 2015 | 409 | 0.040 |
Why?
| | Mental Health | 1 | 2026 | 813 | 0.040 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2000 | 83 | 0.040 |
Why?
| | Mutation | 2 | 2022 | 4130 | 0.040 |
Why?
| | Genital Diseases, Female | 1 | 2019 | 31 | 0.040 |
Why?
| | Neural Inhibition | 1 | 2000 | 180 | 0.040 |
Why?
| | Reproducibility of Results | 3 | 2023 | 3448 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 33 | 0.040 |
Why?
| | DNA Polymerase II | 1 | 2019 | 35 | 0.040 |
Why?
| | Reproductive Health Services | 1 | 2019 | 23 | 0.040 |
Why?
| | Tissue Donors | 1 | 2022 | 427 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 57 | 0.040 |
Why?
| | Pituitary Gland | 1 | 1999 | 149 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2000 | 245 | 0.040 |
Why?
| | Biological Variation, Population | 1 | 2018 | 22 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2018 | 79 | 0.030 |
Why?
| | Testosterone | 1 | 2022 | 417 | 0.030 |
Why?
| | Electroencephalography | 2 | 1999 | 570 | 0.030 |
Why?
| | Morning Sickness | 1 | 2018 | 3 | 0.030 |
Why?
| | Operative Time | 1 | 2019 | 195 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 108 | 0.030 |
Why?
| | Electric Stimulation | 1 | 1999 | 277 | 0.030 |
Why?
| | Midazolam | 1 | 2018 | 73 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2023 | 2017 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2008 | 1415 | 0.030 |
Why?
| | Psychology, Adolescent | 2 | 2008 | 62 | 0.030 |
Why?
| | Carmustine | 1 | 1998 | 52 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1488 | 0.030 |
Why?
| | Memory, Short-Term | 1 | 2000 | 271 | 0.030 |
Why?
| | Frozen Sections | 1 | 2018 | 25 | 0.030 |
Why?
| | Memory | 2 | 1999 | 300 | 0.030 |
Why?
| | Patient Care | 1 | 2019 | 121 | 0.030 |
Why?
| | Aspartic Acid | 1 | 1998 | 88 | 0.030 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 165 | 0.030 |
Why?
| | Thalamus | 1 | 1999 | 132 | 0.030 |
Why?
| | Creatine | 1 | 1998 | 63 | 0.030 |
Why?
| | Legislation, Drug | 1 | 2018 | 73 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 779 | 0.030 |
Why?
| | Hysterosalpingography | 1 | 2017 | 9 | 0.030 |
Why?
| | Fentanyl | 1 | 2018 | 128 | 0.030 |
Why?
| | Sterilization, Tubal | 1 | 2017 | 17 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2019 | 248 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 1998 | 277 | 0.030 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 2231 | 0.030 |
Why?
| | Transcription Factors | 1 | 2005 | 1747 | 0.030 |
Why?
| | Hippocampus | 2 | 2001 | 989 | 0.030 |
Why?
| | Health Surveys | 1 | 2019 | 522 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1386 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 474 | 0.030 |
Why?
| | Hospitals, Private | 1 | 2016 | 12 | 0.030 |
Why?
| | Health Facility Size | 1 | 2016 | 13 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 1998 | 429 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 2110 | 0.030 |
Why?
| | Indians, North American | 1 | 2021 | 567 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2016 | 90 | 0.030 |
Why?
| | AC133 Antigen | 1 | 2015 | 20 | 0.030 |
Why?
| | Marijuana Abuse | 1 | 2019 | 215 | 0.030 |
Why?
| | Self Care | 1 | 2019 | 395 | 0.030 |
Why?
| | Medical Audit | 1 | 2016 | 77 | 0.030 |
Why?
| | Cisplatin | 1 | 1998 | 347 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2016 | 122 | 0.030 |
Why?
| | Marriage | 1 | 2017 | 123 | 0.030 |
Why?
| | Radiotherapy | 1 | 2016 | 210 | 0.030 |
Why?
| | Brain Injuries | 1 | 2001 | 508 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2016 | 189 | 0.030 |
Why?
| | Reaction Time | 4 | 2000 | 438 | 0.030 |
Why?
| | Patient Simulation | 1 | 2015 | 43 | 0.030 |
Why?
| | North America | 1 | 2016 | 307 | 0.030 |
Why?
| | Ileus | 1 | 2015 | 13 | 0.030 |
Why?
| | Cell Count | 1 | 2015 | 321 | 0.030 |
Why?
| | Urinary Retention | 1 | 2015 | 24 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2006 | 528 | 0.030 |
Why?
| | Terminal Care | 1 | 2019 | 284 | 0.030 |
Why?
| | Income | 1 | 2016 | 208 | 0.030 |
Why?
| | Competitive Behavior | 1 | 2015 | 43 | 0.030 |
Why?
| | Female Urogenital Diseases | 1 | 2014 | 7 | 0.030 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2014 | 29 | 0.030 |
Why?
| | Natural Family Planning Methods | 1 | 2014 | 2 | 0.030 |
Why?
| | Morbidity | 1 | 2015 | 323 | 0.030 |
Why?
| | Receptors, Androgen | 1 | 2015 | 149 | 0.030 |
Why?
| | Elective Surgical Procedures | 1 | 2016 | 203 | 0.030 |
Why?
| | Peritoneal Cavity | 1 | 2014 | 30 | 0.030 |
Why?
| | Memory Disorders | 1 | 1996 | 198 | 0.030 |
Why?
| | Laparoscopy | 1 | 2019 | 486 | 0.030 |
Why?
| | Blood Volume | 1 | 2014 | 65 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2015 | 158 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2015 | 244 | 0.030 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 303 | 0.030 |
Why?
| | Acoustic Stimulation | 3 | 2000 | 334 | 0.030 |
Why?
| | Homosexuality, Male | 1 | 1995 | 234 | 0.030 |
Why?
| | Pelvis | 1 | 2015 | 129 | 0.020 |
Why?
| | Surgical Procedures, Operative | 1 | 2016 | 272 | 0.020 |
Why?
| | Administration, Intravaginal | 1 | 2013 | 19 | 0.020 |
Why?
| | Hemostatics | 1 | 2014 | 65 | 0.020 |
Why?
| | Vagina | 1 | 2016 | 206 | 0.020 |
Why?
| | Personnel Selection | 1 | 2015 | 92 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1998 | 2030 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 789 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 2223 | 0.020 |
Why?
| | Drainage | 1 | 2014 | 189 | 0.020 |
Why?
| | Disease Progression | 2 | 2017 | 2892 | 0.020 |
Why?
| | Insurance, Health | 1 | 2016 | 321 | 0.020 |
Why?
| | Child Development | 1 | 1998 | 484 | 0.020 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 406 | 0.020 |
Why?
| | Educational Measurement | 1 | 2016 | 332 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2014 | 538 | 0.020 |
Why?
| | Patient Readmission | 1 | 2018 | 777 | 0.020 |
Why?
| | Insulin | 1 | 2003 | 2526 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2019 | 1171 | 0.020 |
Why?
| | Alcoholism | 1 | 1999 | 838 | 0.020 |
Why?
| | Multiple Sclerosis | 1 | 1998 | 491 | 0.020 |
Why?
| | Perception | 1 | 2015 | 378 | 0.020 |
Why?
| | Text Messaging | 1 | 2014 | 190 | 0.020 |
Why?
| | Escherichia coli | 1 | 2016 | 836 | 0.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 1998 | 703 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 4354 | 0.020 |
Why?
| | Specialty Boards | 1 | 2011 | 42 | 0.020 |
Why?
| | Phenotype | 1 | 1999 | 3216 | 0.020 |
Why?
| | Faculty | 1 | 2011 | 151 | 0.020 |
Why?
| | Registries | 1 | 2019 | 2434 | 0.020 |
Why?
| | Medicaid | 1 | 2014 | 475 | 0.020 |
Why?
| | Interferon beta-1a | 2 | 2000 | 14 | 0.020 |
Why?
| | New York City | 1 | 2009 | 87 | 0.020 |
Why?
| | Urban Health Services | 1 | 2009 | 69 | 0.020 |
Why?
| | Physicians | 1 | 2018 | 961 | 0.020 |
Why?
| | Gravidity | 1 | 2008 | 7 | 0.020 |
Why?
| | Students | 1 | 2014 | 659 | 0.020 |
Why?
| | Injections, Intramuscular | 2 | 2000 | 147 | 0.020 |
Why?
| | Southwestern United States | 1 | 2008 | 93 | 0.020 |
Why?
| | Cross-Cultural Comparison | 1 | 2008 | 84 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 1002 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 3565 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2011 | 932 | 0.020 |
Why?
| | Puberty | 1 | 2008 | 137 | 0.020 |
Why?
| | Cholesterol, HDL | 1 | 2008 | 202 | 0.020 |
Why?
| | Aging | 1 | 1998 | 1992 | 0.020 |
Why?
| | Medical Indigency | 1 | 2006 | 11 | 0.020 |
Why?
| | Urine | 1 | 2007 | 64 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2454 | 0.020 |
Why?
| | Social Perception | 1 | 2008 | 104 | 0.020 |
Why?
| | Urinalysis | 1 | 2007 | 83 | 0.020 |
Why?
| | Forecasting | 1 | 2008 | 391 | 0.020 |
Why?
| | Research Support as Topic | 1 | 2007 | 83 | 0.020 |
Why?
| | Education | 1 | 2007 | 106 | 0.020 |
Why?
| | Social Environment | 1 | 2008 | 254 | 0.010 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2007 | 149 | 0.010 |
Why?
| | Health Services Needs and Demand | 1 | 2008 | 289 | 0.010 |
Why?
| | Child, Preschool | 1 | 2021 | 12017 | 0.010 |
Why?
| | Hospitalization | 1 | 2016 | 2496 | 0.010 |
Why?
| | Triglycerides | 1 | 2008 | 529 | 0.010 |
Why?
| | Universities | 1 | 2007 | 453 | 0.010 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2004 | 33 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2791 | 0.010 |
Why?
| | Attention | 2 | 1999 | 464 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2005 | 369 | 0.010 |
Why?
| | Self Concept | 1 | 2005 | 259 | 0.010 |
Why?
| | Sex Characteristics | 2 | 1999 | 799 | 0.010 |
Why?
| | Research | 1 | 2005 | 435 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2005 | 1344 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 2 | 1997 | 794 | 0.010 |
Why?
| | Blood Pressure | 1 | 2008 | 1785 | 0.010 |
Why?
| | Electromagnetic Fields | 1 | 1999 | 37 | 0.010 |
Why?
| | Schizophrenic Psychology | 1 | 1999 | 102 | 0.010 |
Why?
| | Wechsler Scales | 1 | 1998 | 61 | 0.010 |
Why?
| | Sound Localization | 1 | 1998 | 61 | 0.010 |
Why?
| | Gadolinium | 1 | 1998 | 84 | 0.010 |
Why?
| | Blood Glucose | 1 | 2008 | 2359 | 0.010 |
Why?
| | Cognition | 1 | 2005 | 1286 | 0.010 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 1999 | 297 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1999 | 487 | 0.010 |
Why?
| | Least-Squares Analysis | 1 | 1995 | 73 | 0.010 |
Why?
| | Confidence Intervals | 1 | 1996 | 330 | 0.010 |
Why?
| | Verbal Behavior | 1 | 1995 | 42 | 0.010 |
Why?
| | Space Perception | 1 | 1995 | 82 | 0.010 |
Why?
| | Cognition Disorders | 1 | 1999 | 551 | 0.010 |
Why?
| | Recurrence | 1 | 1998 | 1151 | 0.010 |
Why?
| | Software | 1 | 1999 | 683 | 0.010 |
Why?
|
|
Sheeder's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|